Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | KMO | O15229 | 3/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008951 | 0.84 | KMT2A (0.70) | KMT2ARXFP1MEN1HTTALDH1A1 | |
| SCHEMBL7015132 | 0.83 | SMN1; SMN2 (0.46) | KMT2ARXFP1MEN1HTTALDH1A1 | |
| SCHEMBL17996742 | 0.78 | FFAR1 (0.57) | CYP1A2FFAR1PPARG | |
| SCHEMBL947731 | 0.76 | ALDH1A1 (0.56) | HTTALDH1A1PPARG | |
| SCHEMBL11469526 | 0.74 | PTGS1 (0.59) | KMT2AMEN1ALDH1A1APEX1PPARG | |
| SCHEMBL10580642 | 0.73 | KMT2A (0.54) | KMT2ARXFP1MEN1HTTALDH1A1 | |
| SCHEMBL10580381 | 0.73 | KMT2A (0.54) | KMT2ARXFP1MEN1HTTALDH1A1 | |
| SCHEMBL10583115 | 0.73 | KMT2A (0.54) | KMT2ARXFP1MEN1HTTALDH1A1 | |
| SCHEMBL1201074 | 0.72 | KMT2A (0.71) | KMT2AMEN1HTTALDH1A1FFAR1 | |
| SCHEMBL13870211 | 0.71 | KMT2A (1.00) | KMT2AMEN1ALDH1A1CYP1A2APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1302462-A1 | SULFONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | KMT2A 636/4885RXFP1 363/4885MEN1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.